NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn’s disease (FSCD) Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint Study initiation represents an important milestone in the development of ontunisertib as a

Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period Radiological assessment shows trend for fibrotic stricture stabilization over treatment course Sustained

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company’s Special and Extraordinary General Shareholders’ Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino

Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi’s 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY. 2026 Cantor Global Healthcare Conference.

Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for

Antwerp, Belgium, August 6, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the half year period ended June 30, 2026, and confirmed its outlook for the second half of 2026. Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of

— Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability — Study initiation on track, with first participants expected to be dosed in the second half of 2026 Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB)